{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:07:14Z","timestamp":1787062034937,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lynch syndrome (LS) is an autosomal dominant hereditary cancer syndrome responsible for 2\u20134% of hereditary colorectal cancers (CRC). Mismatch repair protein deficiency (dMMR) is a characteristic feature of LS. It has been associated with a poor response to standard chemotherapy in metastatic colorectal cancer (mCRC). There is currently no LS database to monitor trends of disease in Ireland. We aim to centralise LS data in Ireland to assess the burden of LS in Ireland and guide improvements in prevention and treatment of LS-associated cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective review was carried out including all medical records for LS patients from two of the three cancer genetics clinics in Ireland between 2000 and 2018 was carried out. Clinicopathological data of probands (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200957) and affected family members including demographics, mutation status, cancer diagnosis and outcome was recorded. Statistical analysis was carried out using SPSS software.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-seven families including three-hundred and forty-five individuals affected by cancer were identified. The most common cancers recorded were colorectal (53%), breast (12%) and endometrial (10%). One-hundred and thirty-eight confirmed carriers were identified: 65\n                      <jats:italic>path_MLH1<\/jats:italic>\n                      (47%), 43\n                      <jats:italic>path_MSH2<\/jats:italic>\n                      (31%), 11\n                      <jats:italic>path_MSH6<\/jats:italic>\n                      (8%), 17\n                      <jats:italic>path_PMS2<\/jats:italic>\n                      (12%) and two\n                      <jats:italic>path_EPCAM<\/jats:italic>\n                      (1%). Cancer type varied significantly by gene. Median age of first diagnosis was 44.5\u2009years (range 23\u201381). Half of all deceased patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200911) in this group died within 2.5\u2009years of first diagnosis. These deaths were directly related to cancer in 59% of cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Under diagnosis of LS misses a powerful preventive and therapeutic opportunity. LS causes early onset dMMR cancer diagnoses with substantial societal impact. Implementation of ICBs into treatment policy for this small cohort of dMMR mCRC is an achievable therapeutic goal that may significantly improve survival. A prospective database for LS in Ireland is necessary to maximise prevention in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08263-z","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T13:03:33Z","timestamp":1622034213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The contribution of Lynch syndrome to early onset malignancy in Ireland"],"prefix":"10.1186","volume":"21","author":[{"given":"Alice","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"O\u2019Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Berkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"issue":"1","key":"8263_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0004.2009.01230.x","volume":"76","author":"H Lynch","year":"2009","unstructured":"Lynch H. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medico legal ramifications. Clin Genet. 2009;76(1):1\u201318. https:\/\/doi.org\/10.1111\/j.1399-0004.2009.01230.x.","journal-title":"Clin Genet"},{"issue":"9","key":"8263_CR2","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.21873\/anticanres.10983","volume":"36","author":"F Da Silva","year":"2016","unstructured":"Da Silva F, et al. Update on hereditary colorectal Cancer. Anticancer Res. 2016;36(9):4399\u2013406. https:\/\/doi.org\/10.21873\/anticanres.10983.","journal-title":"Anticancer Res"},{"key":"8263_CR3","unstructured":"NCRI. Cancer factsheets. National Cancer Registry Ireland 2017; Available from: https:\/\/www.ncri.ie\/factsheets [cited 2017 2\/12\/17]"},{"issue":"7","key":"8263_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","volume":"67","author":"P M\u00f8ller","year":"2018","unstructured":"M\u00f8ller P, Sepp\u00e4l\u00e4 TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database. Gut. 2018;67(7):1306\u201316. https:\/\/doi.org\/10.1136\/gutjnl-2017-314057.","journal-title":"Gut"},{"issue":"6","key":"8263_CR5","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1053\/j.gastro.2010.01.054","volume":"138","author":"KW Jasperson","year":"2010","unstructured":"Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138(6):2044\u201358. https:\/\/doi.org\/10.1053\/j.gastro.2010.01.054.","journal-title":"Gastroenterology"},{"key":"8263_CR6","doi-asserted-by":"crossref","unstructured":"Farrell M, et al. Clinical correlation and molecular evaluation confirm that the MLH1 p.Arg182Gly (c.544A>G) mutation is pathogenic and causes Lynch syndrome. Familial Cancer. 2012;11(3):509\u201318.","DOI":"10.1007\/s10689-012-9544-4"},{"key":"8263_CR7","doi-asserted-by":"crossref","unstructured":"Peltom\u00e4ki P. Update on Lynch syndrome genomics. Fam Cancer. 2016;15(3):385\u201393.","DOI":"10.1007\/s10689-016-9882-8"},{"issue":"10","key":"8263_CR8","first-page":"487","volume":"109","author":"J Gleeson","year":"2016","unstructured":"Gleeson J, Gallagher D. Diagnosing Lynch syndrome. Irish Med J. 2016;109(10):487.","journal-title":"Irish Med J"},{"issue":"3","key":"8263_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.clcc.2016.11.001","volume":"16","author":"AK Alex","year":"2017","unstructured":"Alex AK, Siqueira S, Coudry R, Santos J, Alves M, Hoff PM, et al. Response to chemotherapy and prognosis in metastatic colorectal Cancer with DNA deficient mismatch repair. Clin Colorectal Cancer. 2017;16(3):228\u201339. https:\/\/doi.org\/10.1016\/j.clcc.2016.11.001.","journal-title":"Clin Colorectal Cancer"},{"issue":"20","key":"8263_CR10","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219\u201326. https:\/\/doi.org\/10.1200\/JCO.2009.27.1825.","journal-title":"J Clin Oncol"},{"key":"8263_CR11","doi-asserted-by":"crossref","unstructured":"Kam AE, E.C, Emerging role of immunotherapy in the treatment na\u00efve metastatic colorectal cancer patient. . Dig Med Res, 2020. 3(87).","DOI":"10.21037\/dmr-2020-22"},{"key":"8263_CR12","unstructured":"InSiGHT Variant Interpretation Committee: Mismatch Repair Gene Variant Classification Criteria.\u00a0I.S.f.G.H., NM_000249.3(MLH1):c.589-9_589-6delGTTT AND Lynch syndrome. ClinVar; 2013. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/RCV000075778\/."},{"key":"8263_CR13","unstructured":"Mendelics ClinVar Assertion Criteria, NM_000251.3(MSH2):c.913G>A (p.Ala305Thr) AND Lynch syndrome. ClinVar; 2018. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/RCV000076748\/."},{"key":"8263_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-981-15-6891-6_11","volume-title":"Lynch Syndrome","author":"T Nagasaka","year":"2020","unstructured":"Nagasaka T. Immunotherapy for Lynch Syndrome Patients. In: Tomita N, editor. Lynch Syndrome. Singapore: Springer; 2020. p. 117\u201322."},{"key":"8263_CR15","doi-asserted-by":"crossref","unstructured":"Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509\u201320.","DOI":"10.1056\/NEJMoa1500596"},{"key":"8263_CR16","doi-asserted-by":"crossref","unstructured":"Zhao P, et al. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54.","DOI":"10.1186\/s13045-019-0738-1"},{"issue":"23","key":"8263_CR17","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal Cancer. N Engl J Med. 2020;383(23):2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med"},{"issue":"8","key":"8263_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with Nivolumab plus Ipilimumab in DNA mismatch repair\u2013deficient\/microsatellite instability\u2013high metastatic colorectal Cancer. J Clin Oncol. 2018;36(8):773\u20139. https:\/\/doi.org\/10.1200\/JCO.2017.76.9901.","journal-title":"J Clin Oncol"},{"key":"8263_CR19","doi-asserted-by":"crossref","unstructured":"Verma V, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):128.","DOI":"10.1186\/s40425-018-0442-7"},{"key":"8263_CR20","series-title":"Version 3. National Comprehensive Cancer Network","volume-title":"Genetic\/Familial high-risk assessment: Colorectal; Lynch Syndrome guidelines","author":"NCCN guidelines","year":"2017","unstructured":"NCCN guidelines. Genetic\/Familial high-risk assessment: Colorectal; Lynch Syndrome guidelines. Version 3. National Comprehensive Cancer Network 2017; Available from: https:\/\/www2.tri-kobe.org\/nccn\/guideline\/colorectal\/english\/genetics_colon.pdf."},{"issue":"5","key":"8263_CR21","first-page":"829","volume":"188","author":"J Heikki","year":"2000","unstructured":"Heikki J, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;188(5):829\u201334.","journal-title":"Gastroenterology"},{"issue":"3","key":"8263_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1136\/gutjnl-2019-319915","volume":"69","author":"KJ Monahan","year":"2020","unstructured":"Monahan KJ, Bradshaw N, Dolwani S, Desouza B, Dunlop MG, East JE, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)\/Association of Coloproctology of Great Britain and Ireland (ACPGBI)\/United Kingdom Cancer genetics group (UKCGG). Gut. 2020;69(3):411\u201344. https:\/\/doi.org\/10.1136\/gutjnl-2019-319915.","journal-title":"Gut"},{"issue":"5","key":"8263_CR23","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1053\/j.gastro.2018.07.030","volume":"155","author":"HFV Christoph Engel","year":"2018","unstructured":"Christoph Engel HFV, Sepp\u00e4l\u00e4 T, Mecklin J-P, Loeffler M. No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. Gastroenterology. 2018;155(5):1400\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.030.","journal-title":"Gastroenterology"},{"key":"8263_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2018.09.004","volume":"104","author":"DB Vangala","year":"2018","unstructured":"Vangala DB, Cauchin E, Balma\u00f1a J, Wyrwicz L, van Cutsem E, G\u00fcller U, et al. Screening and surveillance in hereditary gastrointestinal cancers: recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)\/world congress on gastrointestinal Cancer, Barcelona, June 2018. Eur J Cancer. 2018;104:91\u2013103. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.004.","journal-title":"Eur J Cancer"},{"issue":"10","key":"8263_CR25","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/s41436-019-0489-y","volume":"21","author":"EJ Crosbie","year":"2019","unstructured":"Crosbie EJ, et al. The Manchester international consensus group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med. 2019;21(10):2390\u2013400. https:\/\/doi.org\/10.1038\/s41436-019-0489-y.","journal-title":"Genet Med"},{"issue":"2","key":"8263_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.5152\/ejbh.2020.5198","volume":"16","author":"M Sheehan","year":"2020","unstructured":"Sheehan M, et al. Investigating the link between Lynch syndrome and breast Cancer. Eur J Breast Health. 2020;16(2):106\u20139. https:\/\/doi.org\/10.5152\/ejbh.2020.5198.","journal-title":"Eur J Breast Health"},{"issue":"8","key":"8263_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/jmedgenet-2015-103216","volume":"52","author":"E Harkness","year":"2017","unstructured":"Harkness E, et al. Lynch syndrome caused by MLH1mutations is associated with an increased risk of breast cancer: a cohort study. J Med Genet. 2017;52(8):553\u20136.","journal-title":"J Med Genet"},{"key":"8263_CR28","series-title":"Version 1.2020. National Comprehensive Cancer Network","volume-title":"Genetic\/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic","author":"NCCN Guidelines","year":"2020","unstructured":"NCCN Guidelines. Genetic\/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. Version 1.2020. National Comprehensive Cancer Network 2020; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf."},{"issue":"3","key":"8263_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10689-012-9537-3","volume":"11","author":"K Pylv\u00e4n\u00e4inen","year":"2012","unstructured":"Pylv\u00e4n\u00e4inen K, Lehtinen T, Kellokumpu I, J\u00e4rvinen H, Mecklin JP. Causes of death of mutation carriers in Finnish Lynch syndrome families. Familial Cancer. 2012;11(3):467\u201371. https:\/\/doi.org\/10.1007\/s10689-012-9537-3.","journal-title":"Familial Cancer"},{"issue":"3","key":"8263_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3238\/arztebl.2013.0032","volume":"110","author":"V Steinke","year":"2013","unstructured":"Steinke V, Engel C, B\u00fcttner R, Schackert HK, Schmiegel WH, Propping P. Hereditary nonpolyposis colorectal cancer (HNPCC)\/Lynch syndrome. Dtsch Arztebl Int. 2013;110(3):32\u20138. https:\/\/doi.org\/10.3238\/arztebl.2013.0032.","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"8263_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10689-016-9897-1","volume":"15","author":"HF Vasen","year":"2016","unstructured":"Vasen HF, et al. Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer: contributions from the Dutch Lynch syndrome registry. Familial Cancer. 2016;15(3):429\u201335. https:\/\/doi.org\/10.1007\/s10689-016-9897-1.","journal-title":"Familial Cancer"},{"issue":"5","key":"8263_CR32","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/path.5422","volume":"250","author":"G Cerretelli","year":"2020","unstructured":"Cerretelli G, Ager A, Arends MJ, Frayling IM. Molecular pathology of Lynch syndrome. J Pathol. 2020;250(5):518\u201331. https:\/\/doi.org\/10.1002\/path.5422.","journal-title":"J Pathol"},{"issue":"3","key":"8263_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10689-004-5811-3","volume":"4","author":"A de la Chapelle","year":"2005","unstructured":"de la Chapelle A. The incidence of Lynch syndrome. Familial Cancer. 2005;4(3):233\u20137.","journal-title":"Familial Cancer"},{"issue":"1","key":"8263_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13053-020-0138-0","volume":"18","author":"P M\u00f8ller","year":"2020","unstructured":"M\u00f8ller P. The prospective Lynch syndrome database reports enable evidence-based personal precision health care. Hered Cancer Clin Pract. 2020;18(1):6\u20136. https:\/\/doi.org\/10.1186\/s13053-020-0138-0.","journal-title":"Hered Cancer Clin Pract"},{"key":"8263_CR35","doi-asserted-by":"crossref","unstructured":"Haraldsdottir S, et al. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nat Commun. 2017;8(14755).","DOI":"10.1038\/ncomms14755"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08263-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08263-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08263-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T13:06:29Z","timestamp":1622034389000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08263-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8263"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08263-z","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All information for this study was obtained by retrospective data review with no patient identification details recorded in the data collection. All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was taken from all proband subjects that were initially contacted by telephone. Chart reviews are currently permitted under the Irish Health Research Regulations (HRR). Ethical approval was granted by the Research Ethics Committee in St. James Hospital Dublin (SJH\/TUH Research Ethics Committee) for this study.Informed consent was taken from all proband subjects that were initially contacted by telephone.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"617"}}